Your browser doesn't support javascript.
loading
Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time-kill experiments: agreement with in silico predictions.
Olsson, Anna; Malmberg, Christer; Zhao, Chenyan; Friberg, Lena E; Nielsen, Elisabet I; Lagerbäck, Pernilla; Tängdén, Thomas.
Afiliação
  • Olsson A; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Malmberg C; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Zhao C; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Nielsen EI; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Lagerbäck P; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Tängdén T; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
J Antimicrob Chemother ; 79(2): 391-402, 2024 02 01.
Article em En | MEDLINE | ID: mdl-38158772
ABSTRACT

OBJECTIVES:

Combination therapy is often used for carbapenem-resistant Gram-negative bacteria. We previously demonstrated synergy of polymyxin B and minocycline against carbapenem-resistant Klebsiella pneumoniae in static time-kill experiments and developed an in silico pharmacokinetic/pharmacodynamic (PK/PD) model. The present study assessed the synergistic potential of this antibiotic combination in dynamic experiments.

METHODS:

Two clinical K. pneumoniae isolates producing KPC-3 and OXA-48 (polymyxin B MICs 0.5 and 8 mg/L, and minocycline MICs 1 and 8 mg/L, respectively) were included. Activities of the single drugs and the combination were assessed in 72 h dynamic time-kill experiments mimicking patient pharmacokinetics. Population analysis was performed every 12 h using plates containing antibiotics at 4× and 8× MIC. WGS was applied to reveal resistance genes and mutations.

RESULTS:

The combination showed synergistic and bactericidal effects against the KPC-3-producing strain from 12 h onwards. Subpopulations with decreased susceptibility to polymyxin B were frequently detected after single-drug exposures but not with the combination. Against the OXA-48-producing strain, synergy was observed between 4 and 8 h and was followed by regrowth. Subpopulations with decreased susceptibility to polymyxin B and minocycline were detected throughout experiments. For both strains, the observed antibacterial activities showed overall agreement with the in silico predictions.

CONCLUSIONS:

Polymyxin B and minocycline in combination showed synergistic effects, mainly against the KPC-3-producing K. pneumoniae. The agreement between the experimental results and in silico predictions supports the use of PK/PD models based on static time-kill data to predict the activity of antibiotic combinations at dynamic drug concentrations.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Polimixina B / Minociclina Limite: Humans Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Polimixina B / Minociclina Limite: Humans Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2024 Tipo de documento: Article